Sage Therapeutics, Inc. announced topline results from PRECEDENT, a double-blind, placebo-controlled Phase 2 study of the investigational oral medicine dalzanemdor (SAGE-718) in people with mild cognitive impairment (MCI) in Parkinson's Disease (PD). The Company expects the following milestones for the dalzanemdor (SAGE-718) Phase 2 clinical development program in 2024: Mid-2024: Report topline data from SURVEYOR Study in people with HD cognitive impairment; Late 2024: Report topline data of LIGHTWAVE Study in people with MCI and mild dementia in AD; Report topline data from DIMENSION Study in people with HD cognitive impaired.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.18 USD | +3.58% | +10.01% | -34.56% |
Apr. 25 | Truist Securities Cuts Sage Therapeutics' Price Target to $18 From $22, Hold Rating Maintained | MT |
Apr. 25 | Transcript : Sage Therapeutics, Inc., Q1 2024 Earnings Call, Apr 25, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-34.56% | 853M | |
-2.63% | 102B | |
+1.62% | 96.29B | |
+2.04% | 22.18B | |
-16.67% | 21.2B | |
-8.68% | 18.31B | |
-38.74% | 17.38B | |
-13.21% | 16.36B | |
+5.41% | 13.97B | |
+33.57% | 12.17B |
- Stock Market
- Equities
- SAGE Stock
- News Sage Therapeutics, Inc.
- Sage Therapeutics, Inc. Announces Topline Results from Phase 2 PRECEDENT Study of DalzanemDor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson's Disease